Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, and its commercial alcohol metabolism product, unbuzzd(TM). The company is focused on advancing innovative therapies for neurodegenerative and metabolic disorders, as well as alcohol misuse.
Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage, an area he believes remains unmet by currently available treatments. The drug candidate has been shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of MS. Quantum BioPharma is preparing for a Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in MS patients, following Phase 1 testing in healthy volunteers. This trial represents a critical step toward potentially offering a new therapeutic option for the estimated 2.8 million people worldwide living with MS.
In addition to its pipeline, Durkacz highlighted unbuzzd(TM), a commercial product designed to accelerate blood alcohol metabolism, currently available in the U.S. market. Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses. This agreement provides a recurring revenue stream that could support further research and development.
The implications of these developments are significant. For the MS community, a successful Phase 2 trial could position Lucid-MS as a first-in-class therapy targeting nerve damage, potentially improving quality of life for patients who currently have limited options. For investors, the unbuzzd royalty structure offers a tangible near-term revenue opportunity while the company advances its pipeline. The market for MS treatments is substantial, with global spending on disease-modifying therapies exceeding $20 billion annually, and any advancement in addressing mobility loss could capture significant market share. Furthermore, unbuzzd taps into the growing demand for health and wellness products aimed at alcohol metabolism, a market with increasing consumer interest.
As Quantum BioPharma moves forward, the upcoming Phase 2 trial will be closely watched by the medical and investment communities. The company's dual focus on a high-need neurological therapy and a commercial wellness product provides a balanced approach to growth. More information about Quantum BioPharma is available in the company's newsroom at https://ibn.fm/QNTM, and the full press release can be viewed at https://ibn.fm/HURxt.
